Phase II study of cediranib in patients with advanced gastrointestinal stromal tumors or soft-tissue sarcoma.
Judson, I Scurr, M Gardner, K Barquin, E Marotti, M Collins, B Young, H Jürgensmeier, J Leahy, Michael G
Judson, I
Scurr, M
Gardner, K
Barquin, E
Marotti, M
Collins, B
Young, H
Jürgensmeier, J
Leahy, Michael G
Citations
Altmetric:
Abstract
Cediranib is a potent VEGF signaling inhibitor with activity against all three VEGF receptors and KIT. This phase II study evaluated the antitumor activity of cediranib in patients with metastatic gastrointestinal stromal tumor (GIST) resistant/intolerant to imatinib, or metastatic soft-tissue sarcomas (STS; ClinicalTrials.gov, NCT00385203).
Affiliation
Description
Date
2014-07-01
Publisher
Collections
Keywords
Type
Article
Citation
Phase II study of cediranib in patients with advanced gastrointestinal stromal tumors or soft-tissue sarcoma. 2014, 20 (13):3603-12 Clin Cancer Res